USD10
CGON Shares
About CG OncologyCG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
USD10
CGON Shares
About CG OncologyCG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Stats
TRADING WINDOW
Closed
OPENS AT
Mar 26 at 1:30 PM GMT+0
MARKET CAP
$5.56B
OPEN PRICE
Not enough data
LOW (1Y)
$14.80
HIGH (1Y)
$69.35
LOW (24H)
$64.15
HIGH (24H)
$66.62
VOLUME (24H)
$412.43K
34.11%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $64.15 | |
1 Week | $64.00 | |
1 Month | $56.90 | |
1 Year | $26.94 |